Towards an advanced cell-based in vitro glioma model system

Abstract

The modulation of tumor growth and development in vitro has always been one of the key factors in the research of the malignant transformation, including gliomas, prevalent and most deadly cancers of the brain. Indeed, cellular and molecular biology research employing in vitro model cell-based systems have great potential to advance both the mechanistic understanding and the treatment of human glial tumors, as it facilitates not only the understanding of glioma biology and its regulatory mechanisms Additionally they promise to afford the screening of the putative anti-tumor agents and alternative treatment approaches in a personalized manner, i.e. by virtue of using the patient-derived tumor material for such tests. However, in order to become reliable and representative, glioma model systems need to move towards including most inherent cancer features such as local hypoxia, specific genetic aberrations, native tumor microenvironment, and the three-dimensional extracellular matrix.

This review starts with a brief introduction on the general epidemiological and molecular characteristics of gliomas followed by an overview of the cell-based in vitro models currently used in glioma research. As a conclusion, we suggest approaches to move to innovative cell-based in vitro glioma models. We consider that main criteria for selecting these approaches should include the adequate resemblance to the key in vivo characteristics, robustness, cost-effectiveness and ease to use, as well as the amenability to high throughput handling to allow the standardized drug screening.

Keywords

brain tumors - glioma - in vitro tumor model system - glioma model - neurospheres - glial cell lines - primary glial cell cultures - cancer stem cells

Publication History

Received: 09 December 2017

Accepted: 14 March 2018

Article published online:
10 May 2021

• References

• 1 Lindsey AT, Freddie B, Rebecca LS. et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108
• 2 Kaprina AD, Starinskiy VV, Petrova GB. Malignant neoplasms in Russia in 2016. Moscow: P. Herzen Moscow Oncology Research Institute publishing house; 2018
• 3 Ostrom QT, Gittleman H, Xu J. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2010–2014. Neuro Onco 2017; 18: iv1-iv89
• 4 Ferlay J, Soerjomataram I, Ervik M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386
• 5 Ostrom QT, Gittleman H, Xu J. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. Neuro Oncol 2016; 18: v1-v75
• 6 Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007; 114: 443-458
• 7 Louis DN, Ohgaki H, Wiestler OD. et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 2007; 114: 97-109
• 8 Ostrom QT, Gittleman H, Fulop J. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology 2015; 17: iv1-iv62
• 9 Stupp R, Mason WP, van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
• 10 Roy S, Lahiri D, Maji T. et al. Recurrent Glioblastoma: Where we stand. South Asian J Cancer 2015; 4: 163-173
• 11 Suzuki H, Aoki K, Chiba K. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015; 47: 458-468
• 12 Schomas DA, Laack NN, Rao RD. et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro-Oncology 2009; 11: 437-445
• 13 Darlix A, Zouaoui S, Virion JM. et al. Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France. J Neuro-Oncology 2014; 120: 547-555
• 14 Tseng MY, Tseng JH, Merchant E. Comparison of effects of socioeconomic and geographic variations on survival for adults and children with glioma. J Neurosurg 2006; 105: 297-305
• 15 Frosina G. Frontiers in targeting glioma stem cells. Eur J Cancer 2011; 47: 496-507
• 16 Gasch С, Ffrench B, O'Leary JJ. et al. Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention. Mol Cancer 16: 1-15
• 17 Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010; 67: 279-283
• 18 Lenting K, Verhaak R, Ter LaanM. et al. Glioma: experimental models and reality. Acta Neuropathol 2017; 133: 263-282
• 19 Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012; 9: 542-548
• 20 Fialkow PJ. Clonal origin of human tumors. Annu Rev Med 1979; 30: 135-143
• 21 Rabkin CS, Janz S, Lash A. et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 1997; 336: 988-993
• 22 Yachida S, Jones S, Bozic I. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117
• 23 Al-Hajj M, Wicha MS, Benito-Hernandez A. et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U.S.A 2003; 100: 3983-3988
• 24 Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res 2006; 66: 1883-1890
• 25 Chen W, Dong J, Haiech J. et al. Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy. Stem Cells Int 2016; 2016: 1740936
• 26 Valent P, Bonnet D, De Maria R. et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012; 12: 767-775
• 27 Chen J, Li Y, Yu TS. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522-526
• 28 Liebelt BD, Shingu T, Zhou X. et al. Glioma Stem Cells: Signaling, Microenvironment, and Therapy. Stem Cells Int 2016; 2016: 7849890
• 29 Fidoamore A, Cristiano L, Antonosante A. et al. Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. Stem Cells Int 2016; 2016: 6809105
• 30 Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila) 2010; 3: 1361-1364
• 31 Gerdes MJ, Sood A, Sevinsky C. et al. Emerging understanding of multiscale tumor heterogeneity. Front Oncol 2014; 4: 366
• 32 Lathia JD, Mack SC, Mulkearns-Hubert EE. Cancer stem cells in glioblastoma. Genes Dev 2015; 29: 1203-1217
• 33 Anido J, Saez-Borderıas A, Gonzalez-Junca A. et al. TGF-Β receptor inhibitors target theCD44high/Id1 high glioma-initiating cell population in human glioblastoma. Cancer Cell 2010; 18: 655-668
• 34 Lathia JD, Gallagher J, Heddleston JM. et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010; 6: 421-432
• 35 Thon N, Damianoff K, Hegermann J. et al. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol Cell Neurosci 2010; 43: 51-59
• 36 Bexell D, Gunnarsson S, Siesjo P. et al. CD133+ and nestin+ tumor-initiating cells dominate in N29 andN32 experimental gliomas. Int J Cancer 2009; 125: 15-22
• 37 Mathieu J, Zhang Z, Zhou W. et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011; 71: 4640-4652
• 38 Ikushima H, Todo T, Ino Y. et al. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem 2011; 286: 41434-41441
• 39 Hagerstrand D, He X, Bradic LindhM. et al. Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro-Oncology 2011; 13: 1178-1191
• 40 Ahlenius H, Kokaia Z. Isolation and generation of neurosphere cultures from embryonic and adult mouse brain. Methods Mol Biol 2010; 633: 241-252
• 41 Galli R. The neurosphere assay applied to neural stem cells and cancer stem cells. Methods Mol Biol 2013; 986: 267-277
• 42 Rahman M, Reyner K, Deleyrolle L. et al. Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. Anatomy Cell Biol 2015; 48: 25-35
• 43 Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011; 8: 486-498
• 44 Patel AP, Tirosh I, Trombetta JJ. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014; 344: 1396-1401
• 45 Venteicher AS, Tirosh I, Hebert C. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 2017; 355: 1391-1403
• 46 Barker N, Bartfeld S, Clevers H. Tissue-resident adult stem cell populations of rapidly self-renewing organs. Cell Stem Cell 2010; 7: 656-670
• 47 Bao S, Wu Q, McLendon RE. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760
• 48 Perazzoli G, Prados J, Ortiz R. et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One 2015; 10: e0140131
• 49 Paik JH, Ding Z, Narurkar R. et al. FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell 2009; 5: 540-553
• 50 Martynoga B, Mateo JL, Zhou B. et al. Epigenomic enhancer annotation reveals a key role for NFIX in neural stem cell quiescence. Genes Dev 2013; 27: 1769-1786
• 51 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131: 803-820
• 52 Brat DJ, Verhaak RG, Aldape KD. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372: 2481-2498
• 53 Chi AS, Batchelor TT, Yang D. et al. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013; 31: e233-236
• 54 Suzuki Y, Takahashi-Fujigasaki J, Akasaki Y. et al. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. Brain Tumor Pathol 2016; 33: 40-49
• 55 Leeper HE, Caron AA, Decker PA. et al. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget 2015; 6: 30295-30305
• 56 Weller M, Weber RG, Willscher E. et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015; 129: 679-693
• 57 Eckel-Passow JE, Lachance DH, Molinaro AM. et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015; 372: 2499-2508
• 58 Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2014; 9: 1-25
• 59 Liu XY, Gerges N, Korshunov A. et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124: 615-625
• 60 Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013; 19: 764-772
• 61 Egan KM, Thompson RC, Nabors L. et al. Cancer susceptibility variants and the risk of adult glioma in a US case–control study. J Neuro-Oncol 2011; 104: 535-542
• 62 Jenkins RB, Xiao Y, Sicotte H. et al. A low-frequency variant at 8q24. 21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 2012; 44: 1122-1125
• 63 Kinnersley B, Labussiere M, Holroyd A. et al. Genome-wide association study identifies multiple susceptibility loci for glioma. Nat Commun 2015; 6: 8559
• 64 Rice T, Zheng S, Decker PA. et al. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro-Oncology 2013; 15: 535-541
• 65 Wrensch M, Jenkins RB, Chang JS. et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009; 41: 905-908
• 66 Shete S, Hosking FJ, Robertson LB. et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009; 41: 899-904
• 67 Walsh KM, Codd V, Smirnov IV. et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 2014; 46: 731-735
• 68 Lu C, Ward PS, Kapoor GS. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478
• 69 Sundarraj N, Schachner M, Pfeiffer SE. Biochemically differentiated mouse glial lines carrying a nervous system specific cell surface antigen (NS-1). Proc Natl Acad Sci U.S.A 1975; 72: 1927-1931
• 70 Dawson G, Sundarraj N, Pfeiffer SE. Synthesis of myelin glycosphingolipids (galactosylceramide and galactosyl (3-O-sulfate) ceramide (sulfatide) by cloned cell lines derived from mouse neurotumors. J Biol Chem 1977; 252: 2777-2779
• 71 Fields KL, Gosling C, Megson M. et al. New cell surface antigens in rat defined by tumors of the nervous system. Proc Natl Acad Sci U.S.A 1975; 72: 1296-1300
• 72 Allen M, Bjerke M, Edlund H. et al. Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med 2016; 8: 354-353
• 73 Torsvik A, Stieber D, Enger PO. et al. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med 2014; 3: 812-824
• 74 De Vries GH, Boullerne AI. Glial cell lines: an overview. Neurochem Res 2010; 35: 1978-2000
• 75 Louis JC, Magal E, Muir D. et al. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J Neurosci Res 1992; 31: 193-204
• 76 Richter-Landsberg C, Heinrich M. OLN-93: a new permanent oligodendroglia cell line derived from primary rat brain glial cultures. J Neurosci Res 1996; 45: 161-173
• 77 Jung M, Kramer E, Grzenkowski M. et al. Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo . Eur J Neurosci 1995; 7: 1245-1265
• 78 Foster LM, Phan T, Verity AN. et al. Generation and analysis of normal and shiverer temperature-sensitive immortalized cell lines exhibiting phenotypic characteristics of oligodendrocytes at several stages of differentiation. J Neurosci Res 1992; 31: 193-204
• 79 Post GR, Dawson G. Characterization of a cell line derived from a human oligodendroglioma. Mol Chem Neuropathol 1992; 16: 303-317
• 80 McLaurin J, Trudel GC, Shaw IT. et al. A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J Neurobiol 1995; 26: 283-293
• 81 Benda P, Lightbody J, Sato G. et al. Differentiated rat glial cell strain in tissue culture. Science 1968; 161: 370-371
• 82 Radany EH, Brenner M, Besnard F. et al. Directed establishment of rat brain cell lines with the phenotypic characteristics of type 1 astrocytes. Proc Natl Acad Sci U.S.A 1992; 89: 6467-6471
• 83 Loo DT, Fuquay JI, Rawson CL. et al. Extended culture of mouse embryo cells without senescence: inhibition by serum. Science 1987; 236: 200-202
• 84 Giard DJ, Aaronson SA, Todaro GJ. et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 51: 1417-1423
• 85 PontÉn J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968; 74: 465-486
• 86 Westermark B, Ponten J, Hugosson R. Determinants for the establishment of permanent tissue culture lines from human gliomas. Acta Pathol Microbiol Scand A 1973; 81: 791-805
• 87 Lee J, Kotliarova S, Kotliarov Y. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403
• 88 Luca AC, Mersch S, Deenen R. et al. Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines. PloS One 2013; 8: e59689
• 89 Storch K, Eke I, Borgmann K. et al. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res 2010; 70: 3925-3934
• 90 Hehlgans S, Lange I, Eke I. et al. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiotherapy oncology: j Eu Soc Therapeutic Radiology Oncology 2009; 92: 371-378
• 91 Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev. Cancer 2008; 8: 180-192
• 92 Gomez-Roman N, Stevenson K, Gilmour L. et al. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Neuro Oncol 2017; 19: 229-241
• 93 Mullins CS, Schneider B, Stockhammer F. et al. Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison. PLoS One 2013; 8: e71070
• 94 Cheng L, Huang Z, Zhou W. et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013; 153: 139-152
• 95 Soda Y, Marumoto T, Friedmann-Morvinski D. et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U.S.A 2011; 108: 4274-4280
• 96 Wang R, Chadalavada K, Wilshire J. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833
• 97 Singec I, Knoth R, Meyer RP. et al. Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat Methods 2006; 3: 801-806
• 98 Gritti A, Galli R, Vescovi AL. Clonal analyses and cryopreservation of neural stem cell cultures. Methods Mol Biol 2008; 438: 173-184
• 99 Brewer GJ, Torricelli JR, Evege EK. et al. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 1993; 35: 567-576
• 100 Luchman HA, Stechishin OD, Dang NH. et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 2012; 14: 184-191
• 101 Rohle D, Popovici-Muller J, Palaskas N. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-630
• 102 Alcantara LSR, Wang Z, Sun D. et al. Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes. Cancer Cell 2015; 28: 429-440
• 103 Lindberg N, Jiang Y, Xie Y. et al. Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells. J Neuro Sci 2014; 34: 14644-14651
• 104 Wang J, Wakeman TP, Lathia JD. et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010; 28: 17-28
• 105 Adorno-Cruz V, Kibria G, Liu X. et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res 2015; 75: 924-929
• 106 Shlush LI, Mitchell A, Heisler L. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 2017; 547: 104-108
• 107 Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cells--from concept to clinical application. Cancer Lett 2013; 338: 32-40
• 108 Holmberg OlaussonK, Maire CL, Haidar S. et al. Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. PLoS One 2014; 9: e106694
• 109 Wee B, Charles N, Holland EC. Animal models to study cancer-initiating cells from glioblastoma. Front Bio Sci (Landmark Ed) 2011; 16: 2243-2258
• 110 Mack SC, Hubert CG, Miller TE. et al. An epigenetic gateway to brain tumor cell identity. Nat Neuro Sci 2016; 19: 10-19
• 111 Irvin DM, McNeill RS, Bash RE, Miller CR. Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models. Brain Pathol 2017; 27: 36-50
• 112 Chen W, Wang D, Du X, He Y, Chen S, Shao Q. et al. Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes. Med Oncol 2015; 32: 43
• 113 Chen W, Xia T, Wang D. et al. Human astrocytes secrete IL-6 to promote glioma migration and invasion through upregulation of cytomembrane MMP14. Oncotarget 2016; 7: 62425-62438
• 114 Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia 2002; 40: 252-259
• 115 Watters JJ, Schartner JM, Badie B. Microglia function in brain tumors. J Neurosci Res 2005; 81: 447-455
• 116 Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 2016; 19: 20-27
• 117 Brooks WH, Markesbery WR, Gupta GD. et al. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 1978; 4: 219-24
• 118 Hao C, Parney IF, Roa WH. et al. Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol 2002; 103: 171-178
• 119 Rodrigues JC, Gonzalez GC, Zhang L. et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010; 12: 351-365
• 120 Jackson C, Ruzevick J, Phallen J. et al. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol 2011; 2011: 732413
• 121 Wischhusen J, Jung G, Radovanovic I. et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002; 62: 2592-2599
• 122 Chahlavi A, Rayman P, Richmond AL. et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res 2005; 65: 5428-5438
• 123 Charles NA, Holland EC, Gilbertson R. et al. The brain tumor microenvironment. Glia 2012; 60: 502-514
• 124 Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507
• 125 Calabrese C, Poppleton H, Kocak M. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82
• 126 Charles N, Ozawa T, Squatrito M. et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010; 6: 141-152
• 127 Hambardzumyan D, Becher OJ, Rosenblum MK. et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo . Genes Dev 2008; 22: 436-448
• 128 Shaw KM, Wrobel C, Brugge J. Use of Three-Dimensional Basement Membrane Cultures to Model Oncogene-Induced Changes in Mammary Epithelial Morphogenesis. J. Mammary Gland Biol 2004; 9: 297-310
• 129 TrÉdan O, Galmarini CM, Patel K, Tannock IF. Drug Resistance and the Solid Tumor Microenvironment. J Natl. Cancer Inst 2007; 99: 1441-1454
• 130 Caliari SR, Burdick JA. A practical guide to hydrogels for cell culture. Nat Methods 2016; 13: 405-414
• 131 Ahmed EM. Hydrogel: Preparation, characterization, and applications: A review. J Adv Res 2015; 6: 105-121
• 132 Dawson E, Mapili G, Erickson K. et al. Biomaterials for stem cell differentiation. Adv Drug Deliv Rev 2008; 60: 215-228
• 133 Kiefer JA, Farach-Carson MC. Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: Implications for enhanced growth in the bone microenvironment. Matrix Bio 2001; 20: 429-437
• 134 Menke A, Philippi C, Vogelmann R. et al. Down-Regulation of E-Cadherin Gene Expression by Collagen Type I and Type III in Pancreatic Cancer Cell Lines. Cancer Res 2001; 61: 3508-3517
• 135 Kim YJ, Bae HI, Kwon OK. et al. Three-dimensional gastric cancer cell culture using nanofiber scaffold for chemosensitivity test. Int J Biol Macromol 2009; 45: 65-71
• 136 Sun W, Incitti T, Migliaresi C. et al. Viability and neuronal differentiation of neural stem cells encapsulated in silk fibroin hydrogel functionalized with an IKVAV peptide. J Tissue Eng Regen Med 2017; 11: 1532-1541
• 137 Musah S, Morin SA, Wrighton PJ. et al. Glycosaminoglycan-binding hydrogels enable mechanical control of human pluripotent stem cell self-renewal. ACS Nano 2012; 6: 10168-10177
• 138 Souza GR, Molina JR, Raphael RM. et al. Three-dimensional tissue culture based on magnetic cell levitation. Nat. Nanotechnol 2010; 5: 291-296
• 139 Carpenter PM, Dao AV, Arain ZS. et al. Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5). Mol. Cancer Res 2009; 7: 462-475
• 140 Zhou Z, Wang J, Cao R. et al. Impaired Angiogenesis, Delayed Wound Healing and Retarded Tumor Growth in Perlecan Heparan Sulfate-Deficient Mice. Cancer Res 2004; 64: 4699-4702
• 141 Miyamoto H, Murakami T, Tsuchida K. et al. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004; 28: 38-44
• 142 Nguyen TV, Sleiman M, Moriarty T. et al. Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. Biomaterials 2014; 35: 5749-5759
• 143 Vinci M. et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012; 10: 29-49
• 144 Rybtsov S, Batsivari A, Bilotkach K. et al. Tracing the Origin of the HSC Hierarchy Reveals an SCF-Dependent, IL-3-Independent CD43- Embryonic Precursor. Stem Cell Rep 2014; 3: 489-501
• 145 Herter S, Morra L, Schlenker R. et al. A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. Cancer Immunol Immunother 2017; 66: 129-140
• 146 Hirt C, Papadimitropoulos A, Mele V. et al. “In vitro” 3D models of tumor-immune system interaction. Adv Drug Deliv Rev 2014; 79-80: 145-54
• 147 Ma FX, Chen F, Chi Y. et al. Culture of pancreatic progenitor cells in hanging drop and on floating filter. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2013; 35: 270-274
• 148 Ingthorsson S, Sigurdsson V, Fridriksdottir JRA. Endothelial cells stimulate growth of normal and cancerous breast epithelial cells in 3D culture. BMC Res 2010; 3: 184-195
• 149 Li L, Lu YJ. Optimizing a 3D Culture System to Study the Interaction between Epithelial Breast Cancer and Its Surrounding Fibroblasts. Cancer 2011; 2: 458-466
• 150 Touboul C, Raphael L, Farsi HAI. et al. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl. Med 2013; 11: 28-39
• 151 Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J Vis Exp 2011; 54: e2937
• 152 VÖrsmann H, Groeber F, Walles H. et al. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death Dis 2013; 4: e719
• 153 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
• 154 Upreti M, Jamshidi-Parsian A, Koonce NA. et al. Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics. Transl Oncol 2011; 4: 365-376
• 155 Ramgolam K, Lauriol J, Lalou C. et al. Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS One 2011; 6: e18784
• 156 Giannattasio A, Weil S, Kloess S. et al. Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids. BMC Cancer 2015; 15: 351-363
• 157 Marchwicka A, Cebrat M, Sampath P. et al. Perspectives of Differentiation Therapies of Acute Myeloid Leukemia: The Search for the Molecular Basis of Patients' Variable Responses to 1,25-Dihydroxyvitamin D and Vitamin D Analogs. Frontiers in Oncology 2014; 4: 125-136
• 158 Caren H, Beck S, Pollard SM. Differentiation therapy for glioblastoma³too many obstacles?. Mol Cellr Oncol 2016; 3: e1124174